In human cultured monocytic cells stimulated by cytokines, CD43 was demonstrated to exhibit a modification of sialylated epitopes (dys-sialylation) [Soler et al: Leukoc Biol 1997;61:609–618]. Therefore, we chose to investigate CD43 behavior on patients who present pathological status implicating monocytes after renal graft (KTR). We performed flow cytometry after immune staining using monoclonal antibodies to CD43 sialic acid-dependent (L60) and -independent (L10) epitopes. Compared to normal controls, mean fluorescence intensity was never altered on lymphocytes. Conversely, on monocytes, we found different profiles with L60: 26% of patients having normal CD43 expression, 54% displayed decreased values and 20% had a double population of monocytes, the major one being normal and the minor one with a very low staining. Decreased values were more frequent among KTR during the first 3 months following transplantation. L10 immunostaining was not altered on monocytes in patients with low values of CD43 staining by L60, confirming that the mechanism involved was a CD43 dys-sialylation. We investigated a possible role of cyclosporin (CsA) on human monocytic (THP-1) and lymphoid (Jurkat) cell lines. CsA decreases CD43 expression in monocytic and not in lymphoid cell lines and could be responsible for the specific dys-sialylation of KTR monocytes. Whatever, CD43 dys-sialylation might lead to functional abnormalities of monocytes in KTR, possibly involving the adhesion process.

Keywords:
CD43, Monocytes, Lymphocytes, Kidney transplants, Cyclosporin
1.
Park JK, Rosenstein YJ, Remold-O’Donnell E, Bierer BE, Rosen FS, Burakoff SJ: Enhancement of T-cell activation by the CD43 molecule whose expression is defective in Wiskott-Aldrich syndrome. Nature 1991;350:706–709.
2.
Remold-O’Donnell E, Rosen FS, Kenney DM: Defects in Wiskott-Aldrich syndrome blood cells. Blood 1996;87:2621–2631.
3.
Carlsson SR, Fukuda M: Isolation and characterization of leukosialin, a major sialoglycoprotein on human leukocytes. J Biol Chem 1986;261:12779–12786.
4.
Cyster JG, Shotton DM, Williams AF: The dimensions of the T lymphocytes glycoprotein leukosialin and identification of linear protein epitopes that can be modified by glycosylation. EMBO J 1991;10:893–902.
5.
Manjunath N, Johnson RS, Staunton DE, Pasqualini R, Ardman B: Targeted disruption of CD43 gene enhances T lymphocyte adhesion. J Immunol 1993;151:1528–1534.
6.
Manjunath N, Correa M, Ardman M, Ardman B: Negative regulation of T cell adhesion and activation by CD43. Nature 1995;377:535–538.
7.
Sànchez-Mateos P, Campanero MR, del Pozo MA, Sànchez-Madrid F: Regulatory role of CD43 leukosialin on integrin-mediated T-cell adhesion to endothelial and extracellular matrix ligands and its polar redistribution to a cellular uropod. Blood 1995;86:2228–2239.
8.
Del Pozo MA, Sanchez-Mateos P, Nietto M, Sanchez-Madrid F: Chemokines regulate cellular polarization and adhesion receptor redistribution during lymphocyte interaction with endothelium and extracellular matrix. Involvement of cAMP signalling pathway. J Cell Biol 1994;131:495–508.
9.
Soler M, Merant C, Servant C, Fraterno M, Allasia C, Lissitzky JC, Bongrand P, Foa C: Leukosialin (CD43) behavior during adhesion of human macrophage to red blood cells. J Leukoc Biol 1997;61:609–618.
10.
Tsuchiya S, Yamabe M, Yamaguchi Y, Kobayashi Y, Konno T, Tada K: Establishment and characterization of a human acute monocytic leukemia cell line THP-1. Int J Cancer 1980;26:171–176.
11.
Suthanthiran M, Morris RE, Strom TB: Immunosuppressants: Cellular and molecular mechanisms of action. Am J Kidney Dis 1996;28:159–172.
12.
Remold-O’Donnell E, Zimmerman C, Kenney D, Rosen FS: Expression on blood cells of sialophorin, the surface glycoprotein that is defective in Wiskott-Aldrich syndrom. Blood 1987;70:104–109.
13.
Remold-O’Donnell E, Kenney DM, Parkman R, Cairns L, Savage B, Rosen F: Characterisation of a human lymphocyte surface sialoglycoprotein that is defective in Wiskott-Aldrich syndrome. J Exp Med 1984;159:1705–1723.
14.
Lefèbvre JC, Giordanengo V, Limouse M, Doglio A, Cucchiarini M, Monpoux F, Mariani R, Peyron JF: Altered glycosylation of leukosialin, CD43, in HIV1-infected cells of the CEM line. J Exp Med 1994;180:1609–1617.
15.
Howell DN, Vinita A, Jones L, Blow O, Sanfilippo FP: Differential expression of CD43 (leukosialin, sialophorin) by mononuclear phagocyte populations. J Leukoc Biol 1994;55:536–544.
16.
Ahuja V, Miller SE, Howell DN: Identification of two subpopulations of rat monocytes expressing disparate molecular forms and quantities of CD43. Cell Immunol 1995;163:59–69.
17.
Bazil V, Strominger JL: CD43, the major sialoglycoprotein of human leukocytes, is proteolytically cleaved from the surface of stimulated lymphocytes and granulocytes. Proc Natl Acad Sci USA 1993;90:3792–3796.
18.
Remold-O’Donnell E, Parent D: Two proteolytic pathways for down-regulation of the barrier molecule CD43 on human neutrophils. J Immunol 1994;152:3595–3605.
19.
Kerman RH, Flechner SM, Van Buren CT, Lorbert MI, Kahan B: Immuno-regulatory mechanisms in cyclosporine-treated renal allograft recipients. Transplantation 1987;43:205–210.
20.
Snyder DS, Wright CL, Ting C: Inhibition of human monocyte antigen presentation, but not HLA-DR expression by cyclosporine. Transplantation 1987;44:407–411.
21.
Reisman L, Cooper D, Lieberman KV, Martinelli GP: Cyclosporin suppresses IL-1 production by isolated human monocytes and by the human hystiocytoma cell line THP-1. Transplant Proc 1990;22:1744–1746.
22.
Yonish-Rouach E, Fischer DG, Rubinstein M: Cyclosporin A regulates the expression of HLA-DR on human monocytes by two different mechanism. Cell Immunol 1991;134:402–413.
23.
McKenna RM, Ruchd DN, Bakkestade-Legare P, Jeffery JR: Interleukin-2, interferon and lymphotoxin in renal transplant recipients. Transplantation 1998;45:76–82.
24.
Leimenstoll G, Engemann R, Gassel J, Hoffmann S, Preusse D, Schlag H, Schlag H, Niedermayer W: Cytokin secretion capacity of mononuclear cells in renal transplant recipients: The effect of two different dose schedules. Transplant Proc 1993;25:2666–2668.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.